Our top pick for
Building a portfolio
Agenus Inc is a biotechnology business based in the US. Agenus shares (AGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Agenus employs 359 staff and has a trailing 12-month revenue of around USD$88.2 million.
|52-week range||USD$2.28 - USD$5.45|
|50-day moving average||USD$3.395|
|200-day moving average||USD$3.7399|
|Wall St. target price||USD$7.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.906|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$88.2 million|
|Gross profit TTM||USD$-56,796,000|
|Return on assets TTM||-39.21%|
|Return on equity TTM||0%|
|Market capitalisation||USD$573.1 million|
TTM: trailing 12 months
There are currently 24.0 million Agenus shares held short by investors – that's known as Agenus's "short interest". This figure is 0.8% down from 24.2 million last month.
There are a few different ways that this level of interest in shorting Agenus shares can be evaluated.
Agenus's "short interest ratio" (SIR) is the quantity of Agenus shares currently shorted divided by the average quantity of Agenus shares traded daily (recently around 3.0 million). Agenus's SIR currently stands at 7.93. In other words for every 100,000 Agenus shares traded daily on the market, roughly 7930 shares are currently held short.
However Agenus's short interest can also be evaluated against the total number of Agenus shares, or, against the total number of tradable Agenus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Agenus's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Agenus shares in existence, roughly 120 shares are currently held short) or 0.1298% of the tradable shares (for every 100,000 tradable Agenus shares, roughly 130 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Agenus.
Find out more about how you can short Agenus stock.
We're not expecting Agenus to pay a dividend over the next 12 months.
Agenus's shares were split on a 1:6 basis on 2 October 2011. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Agenus shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Agenus shares which in turn could have impacted Agenus's share price.
Over the last 12 months, Agenus's shares have ranged in value from as little as $2.28 up to $5.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agenus's is 1.3707. This would suggest that Agenus's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Steps to owning and managing PNRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing PINC, with 24-hour and historical pricing before you buy.
Steps to owning and managing POAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTS, with 24-hour and historical pricing before you buy.
Steps to owning and managing PTMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPOP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLYA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAGP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.